



**SZABO  
SCANDIC**

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](http://linkedin.com/company/szaboscandic)



# SRD5A3 siRNA (m): sc-153818



The Power to Question

## BACKGROUND

Representing approximately 6% of the human genome, chromosome 4 contains nearly 900 genes. Notably, the Huntington gene, which is found to encode an expanded glutamine tract in cases of Huntington's disease, is on chromosome 4. FGFR-3 is also encoded on chromosome 4 and has been associated with thanatophoric dwarfism, achondroplasia, Muenke syndrome and bladder cancer. Chromosome 4 is also tied to Ellis-van Creveld syndrome, methylmalonic acidemia and polycystic kidney disease. Chromosome 4 reportedly contains the largest gene deserts (regions of the genome with no protein encoding genes) and has one of the two lowest recombination frequencies of the human chromosomes.

## REFERENCES

1. Hillier, L.W., Graves, T.A., Fulton, R.S., Fulton, L.A., Pepin, K.H., Minx, P., Wagner-McPherson, C., Layman, D., Wylie, K., Sekhon, M., Becker, M.C., Fewell, G.A., et al. 2005. Generation and annotation of the DNA sequences of human chromosomes 2 and 4. *Nature* 434: 724-731.
2. Cowan, C.M. and Raymond, L.A. 2006. Selective neuronal degeneration in Huntington's disease. *Curr. Top. Dev. Biol.* 75: 25-71.
3. Chandler, R.J., Sloan, J., Fu, H., Tsai, M., Stabler, S., Allen, R., Kaestner, K.H., Kazazian, H.H. and Venditti, C.P. 2007. Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle. *BMC Med. Genet.* 8: 64.
4. Cunningham, M.L., Seto, M.L., Ratisoontorn, C., Heike, C.L. and Hing, A.V. 2007. Syndromic craniosynostosis: from history to hydrogen bonds. *Orthod. Craniofac. Res.* 10: 67-81.
5. de Frutos, C.A., Vega, S., Manzanares, M., Flores, J.M., Huertas, H., Martínez-Frías, M.L. and Nieto, M.A. 2007. Snail1 is a transcriptional effector of FGFR-3 signaling during chondrogenesis and achondroplasias. *Dev. Cell* 13: 872-883.
6. Ruiz-Perez, V.L., Blair, H.J., Rodriguez-Andres, M.E., Blanco, M.J., Wilson, A., Liu, Y.N., Miles, C., Peters, H. and Goodship, J.A. 2007. EVC is a positive mediator of Ihh-regulated bone growth that localises at the base of chondrocyte cilia. *Development* 134: 2903-2912.
7. Stack, E.C., Dedeoglu, A., Smith, K.M., Cormier, K., Kubilus, J.K., Bogdanov, M., Matson, W.R., Yang, L., Jenkins, B.G., Luthi-Carter, R., Kowall, N.W., Hersch, S.M., Beal, M.F. and Ferrante, R.J. 2007. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. *J. Neurosci.* 27: 12908-12915.
8. Versteegh, F.G., Buma, S.A., Costin, G., de Jong, W.C. and Hennekam, R.C. 2007. Evc Working Party. Growth hormone analysis and treatment in Ellis-van Creveld syndrome. *Am. J. Med. Genet. A* 143A: 2113-2121.
9. Doherty, E.S., Lacbawan, F., Hadley, D.W., Brewer, C., Zalewski, C., Kim, H.J., Solomon, B., Rosenbaum, K., Domingo, D.L., Hart, T.C., Brooks, B.P., Immken, L., Lowry, R.B., Kimonis, V., Shanske, A.L., Jehee, F.S., et al. 2007. Muenke syndrome (FGFR-3-related craniosynostosis): Expansion of the phenotype and review of the literature. *Am. J. Med. Genet. A* 143A: 3204-3215.

## CHROMOSOMAL LOCATION

Genetic locus: Srd5a3 (mouse) mapping to 5 C3.3.

## PRODUCT

SRD5A3 siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 µM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see SRD5A3 shRNA Plasmid (m): sc-153818-SH and SRD5A3 shRNA (m) Lentiviral Particles: sc-153818-V as alternate gene silencing products.

## STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 µl of the RNase-free water provided. Resuspension of the siRNA duplex in 330 µl of RNase-free water makes a 10 µM solution in a 10 µM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## APPLICATIONS

SRD5A3 siRNA (m) is recommended for the inhibition of SRD5A3 expression in mouse cells.

## SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor SRD5A3 gene expression knockdown using RT-PCR Primer: SRD5A3 (m)-PR: sc-153818-PR (20 µl). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.